Isturisa (Osilodrostat)

Osilodrostat blocks the enzyme 11β‑hydroxylase (CYP11B1) in the adrenal cortex, which is essential for the final step of cortisol synthesis. Inhibiting this enzyme reduces the amount of cortisol produced, thereby addressing the hormonal imbalance in Cushing's disease.

The dosage of Isturisa is individualized. A qualified prescriber determines the starting dose and any subsequent adjustments based on the patient’s cortisol levels, clinical response, and tolerance. Patients should follow the prescribing clinician’s instructions exactly.

Safety data for osilodrostat in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Isturisa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Isturisa (osilodrostat) is a 11β‑hydroxylase inhibitor, whereas other agents such as ketoconazole or metyrapone inhibit different steps of steroidogenesis. Osilodrostat offers a targeted mechanism with once‑daily oral dosing, but the choice of therapy depends on efficacy, safety profile, drug interactions, and individual patient factors.

Isturisa tablets should be stored at ambient temperature, below 25 °C, in the original blister pack. Protect them from moisture, heat, and direct sunlight to maintain potency throughout the shelf life.

Isturisa is taken orally, usually once daily with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with water and not chewed or crushed unless specifically instructed.

The most serious risks include adrenal insufficiency, severe hypertension, hypokalemia, and QT‑interval prolongation, all of which may require immediate medical attention. Regular monitoring of cortisol, electrolytes, blood pressure, and cardiac rhythm helps mitigate these risks.

Isturisa is contraindicated in patients with known hypersensitivity to osilodrostat or any tablet excipients, and in those with uncontrolled severe hypertension or significant cardiac arrhythmias. Caution is also advised for patients with pre‑existing adrenal insufficiency or electrolyte disturbances.